Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific has a moat-worthy stable of innovative healthcare products and has strong profitability.

How Boston Scientific Could Give You A Worry-Free Retirement

MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m.

Boston Scientific Announces Conference Call Discussing Second Quarter 2021 Results

Boston Scientific (BSX) currently holds an equity stake of roughly 27%.

Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake

MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David S.

Boston Scientific Elects David S. Wichmann To Board Of Directors

Big Lots

Gilead Sciences

Qurate Retail Inc

Suncor Energy

The following are the best-performing stocks over the past six months that have a long-term presence in more than five gurus' portfolios.

5 Rising Stocks in Gurus' Portfolios

MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

Becton, Dickinson and Co.

Edwards Lifesciences

Medtronic

Merit Medical Systems

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

We believe that the stock price of ​Boston Scientific (NYSE: BSX) is undervalued at current levels of $43. BSX stock is up 65% from the levels of around $26 it was at on March 23, 2020, underperforming the broader markets with the S&P 500 rising 89% over the same period.

Here's Why Boston Scientific Is Undervalued At $43 Levels

Which one of these medical device makers is better poised for a breakout year?

Better Buy: Medtronic or Boston Scientific?

The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.

Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows

Molson Coors Brewing

Autodesk

Allied Esports Entertainment Inc

Exact Sciences

Gap Inc

Constellation Brands

Stryker

With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.

Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls

Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope

MARLBOROUGH, Mass., May 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021.

Boston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference

MARLBOROUGH, Mass., May 18, 2021 /PRNewswire/ -- Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI), of the Boston Scientific (NYSE: BSX) ACURATE neo2™ Aortic Valve System within the investigator-initiated Early neo2 Registry1 and ITAL-neo Registry2 studies.

Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System

The stock price of Boston Scientific has corrected 3.5% over the last five trading sessions, and the dip appears to be a good buying opportunity in our view. Not only did the company post an upbeat performance in Q1, it has seen multiple positive developments of late.

What's New With Boston Scientific Stock?

Like most medical device manufacturers, Boston Scientific Corp. ( BSX , Financial) also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surgeries due to the Covid-19 pandemic. The company witnessed its fair share of disruptions, but appears to be on a recovery path, delivering better-than-expected results for the first quarter.

Boston Scientific: Is The Expected Recovery Factored Into the Price?

MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

Boston Scientific Announces May Conference Schedule

Asensus Surgical

Intuitive Surgical

Johnson & Johnson

Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).

Innovation Drives Robotic-Assisted Surgery: 5 Stocks to Watch

Boston Scientific Corporation (NYSE: BSX) Q1 sales grew by 5.9% (organically) to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter, better than the consensus estimate $2.62 billion. EPS of $0.37 beat the analyst consensus estimate of $0.31 versus $0.28 a year ago.

Boston Scientific Stock Jumps On Q1 Earnings Beat, Improved Guidance

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q1 2021 Results - Earnings Call Transcript

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

Boston Scientific Corp. shares rose 1.5% in premarket trade Wednesday, after the medical device company beat estimates for its first-quarter earnings and offered upbeat guidance. The company said it had net income of $327 million, or 23 cents a share, in the quarter, up from $11 million, or 1 cent a share, in the year-earlier period.

Boston Scientific tops Q1 estimates and offers upbeat guidance

MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.

Boston Scientific Announces Results For First Quarter 2021

Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Boston Scientific (BSX) Might Surprise This Earnings Season

Abbott Labs

Align Technology

Quest Diagnostics

Hologic

Integra LifeSciences Holdings

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

News for Boston Scientific Stock (BSX)